Filing Flows › Financials › Z Squared (ZSQR)

Z Squared (ZSQR) earnings and revenue breakdown

Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · Z Squared (ZSQR) Q2 2026 earnings results →

Q2 2026 667¢ of every $1 of revenue lost · operating margin -672.2%

Z Squared made $1.5M in Q2 2026. Operating margin -672.2%, net loss $9.8M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Quarterly history

Charts

Interactive views

The same charts as the app — open one to draw it.

Customers and suppliers named in filings

Buys from

• MSFT · Stated in 10-K (named, share not stated) · source

About Z Squared

General. On April 24, 2026 (the “Closing” or the “Closing Date”), Z Squared Inc. (the “Company”), formerly known as Coeptis Therapeutics Holdings, Inc., completed the business combination contemplated by the Agreement and Plan of Merger, dated as of April 25, 2025 (the “Merger Agreement”), by and among the Company, CP Merger Sub Inc., a Wyoming corporation and wholly owned subsidiary of the Company (“Merger Sub”), and Z Squared, Inc., a Wyoming corporation. At the effective time of the merger (the “Effective Time”), Merger Sub merged with and into Z Squared, Inc., which survived the merger as a wholly owned subsidiary of the Company and was renamed Z Squared OpCo Inc. (“OpCo”) (the “Merger”). In connection with the Closing, the Company changed its corporate name from “Coeptis Therapeutics Holdings, Inc.” to “Z Squared Inc.”

In its own words, from its 10-Q, filed Aug 13, 2026.

Z Squared against its Finance Services peers

The largest companies of the same SEC industry, each at its latest quarter. Operating margin: -672.2% against the peers' median 5.1%.

Source: Z Squared 10-Q on SEC EDGAR · CIK 1759186 · Finance Services

中文版：Z Squared（ZSQR）财报

Español · Français